Mallinckrodt Medical/Sandoz Pharma
Enter agreement to develop and radiolabel molecules for radiodiagnostics and radiotherapeutic products. The deal, announced Dec. 16 by Mallinckrodt parent IMCERA (Northbrook, Ill.) and Sandoz Pharma Ltd. (Basel) gives Mallinckrodt exclusive worldwide rights to diagnostic products generated by the collaboration; Sandoz will receive exclusive rights to any therapeutic products commercialized. Financial terms were not disclosed. The contract, initially for five years with possible extensions, grows out of a March 1991 agreement for Mallinckrodt to develop and market an Indium-111 radiolabeled cancer imaging agent (OctreoScan-111) based on Sandoz' Sandostatin (octreotide). Mallinckrodt filed an NDA for OctreoScan-111 for abdominal tumor imaging on Oct. 22 ("The Pink Sheet" Oct. 26, T&G- 1).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth